Naar hoofdcontent gaan Welcome to CSL Behring Russia Read more Forty years of bleeding control in von Willebrand disease Contacts: We are interested in your questions and concerns. NLD-CRP-0003 CSL Behring © 2021 Terms of Use Privacy Policy map of site Please note that disabling the use of cookies may significantly limit your ability to use the site. For more information, please refer to the Privacy Policy . At the end of this information message, you can disable the use of cookies .

Product Pipeline CSL Behring R&D Product Pipeline Focused on Innovation CSL Behring is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma fractionation, recombinant technology, and cell and gene therapy to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in five Therapeutic Areas - Immunology, Hematology, Cardiovascular and Metabolic, Respiratory and Transplant. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth. Core Capabilities Immunology Hematology Cardiovascular and Metabolic Transplant Respiratory Outlicensed Programs All TA's Phase 1 Phase 2 Phase 3 Registration / Post-Registration R&D Portfolio CSL324 Anti-G-CSFR mAb (HS) CSL730 Recombinant Trivalent Human IgG1 Fc Multimer* CSL889 Hemopexin (SCD) CSL787 Nebulized Ig (NCFB) CSL311 Anti-Beta Common mAb (Asthma) ASLAN004 Anti-IL-13R mAb (AD) HIZENTRA® (SSc) Garadacimab Anti-FXIIa mAb (ILD/IPF) CSL346 Anti-VEGFB mAb (DKD) Mavrilimumab Anti-GM-CSFR mAb (GCA, COVID-19)* Garadacimab Anti-FXIIa mAb (HAE) HIZENTRA® (DM) EtranaDez Etranacogene dezaparvovec (Hem B) KCENTRA® 4F-PCC (Trauma) CSL112 ApoA-I (AMI) Clazakizumab Anti-IL-6 mAb (AMR) CSL964 Alpha-1 Antitrypsin (Prevention of GvHD) CSL964 Alpha-1 Antitrypsin (Treatment of GvHD)* HAEGARDA® (HAE) HIZENTRA® (SCIg) 20% Liquid PRIVIGEN® (IVIg) 10% Liquid AFSTYLA® rFVIII (Hem A) IDELVION® rFIX-FP (Hem B) ZEMAIRA®/RESPREEZA® Alpha-1 Proteinase Inhibitor (AAT Deficiency) Our Products Discover CSL Behring's life-saving therapies. Learn More R&D Capabilities See what we're working on. Learn More What is a Clinical Trial? Discover how we test and verify our products. Learn More Get our latest Vita stories in your inbox Email Contact CSL, All Rights Reserved © 2021 Terms of Use Cookie Policy Privacy Policy Accessibility Statement Patents Sitemap By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Accept All Cookies